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ABSTRACT
INTRODUCTION: The objective of this pilot study was to evaluate the effects of
a new micronutrient, glutamine, pre- and probiotic enriched liquid nutritional
supplement on the nutritional status and immunity of adults living with HIV/AIDS. The
study was designed as a prospective randomised double-blind placebo-controlled
trial. Subjects were HIV-infected male and female adult volunteers (n = 47) from
a community-based hospice centre in a peri-urban area in a resource-poor setting
and were included irrespective of duration or clinical stage of HIV/AIDS. None of the
subjects received antiretroviral therapy.
METHOD: The intervention involved the daily ingestion of 40g (200 ml reconstituted)
of either the enriched test product or an lsocalorie carbohydrate placebo for a period
of 12 weeks. Anthropometric assessment (weight, height and triceps skinfold
thickness; mid-upper arm, waist and hip circumferences) was performed at baseline
and thereafter every 4 weeks (4 times). Biochemical (serum total protein, serum
albumin and C-reactive protein) and haematological (full blood count and
immunophenotyping) assessment was performed at baseline and again after
week 12.
RESULTS: Statistical analysis of baseline values was performed with Wilcoxon
two-sample tests for comparison between the supplemented and placebo groups.
Outcomes were evaluated using analysis of variance with Shapiro-Wilk tests and
thereafter either pair-wise t-tests or sign tests (for nonparametric data) were used.
Thirty-two subjects completed the trial, 14 in the supplemented group and 18 in the
placebo group. Weight increased significantly in the supplemented group
(2.73 ± 3.53 kg, P = 0.013). Triceps skinfold thickness increased significantly in both
the supplemented (p = 0.047) and placebo group (p = 0.001). No other significant
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anthropometric change was observed. Serum albumin increased significantly in the
supplemented group (p = 0.003) and was associated with a significant decline in
C-reactive protein (p = 0.028). Haemoglobin decreased significantly in both groups.
A significant decline in CD4+ count was observed in the placebo group while the
decline in the supplemented group did not reach significance.
CONCLUSION: Oral nutritional supplementation in limited quantities was well
tolerated for a period of 3 months. This study demonstrated that an enriched
nutritional supplement was able to promote weight gain and ameliorate
hypoalbuminaemia and possibly inflammation in adults living with HIV/AIDS in the
short to medium term. The enriched nutritional supplement does not appear to have
an effect on the immunity of people with HIV/AIDS. The small sample is a limitation
of the study and the conclusions pertain to the test product as a whole and not to any
of its respective ingredients. Although further studies are required to evaluate
long-term feasibility, these findings suggest that the use of an enriched nutritional
supplement has a role in the management of weight loss in persons with HIV/AIDS.
Stellenbosch University http://scholar.sun.ac.za
vOPSOMMING
INLEIDING: Die doel van hierdie loodsstudie was om die uitwerking van 'n nuwe
mikronutriënt, glutamien, pre- en probiotika verrykte voedingsaanvulling in vloeistof
vorm te ondersoek. Die studie is ontwerp as 'n prospektiewe ewekansige
dubbelblinde plasebogekontroleerde toets. Proefpersone was MIV-geïnfekteerde
manlike and vroulike vrywilligers (n = 47) van 'n gemeenskapsgebaseerde hospitium
in a semi-stedelike gebied in 'n hulpbron-arme omgewing. Proefpersone is ingesluit
ongeag die duur of kliniese graad van MIVNIGS. Geen proefpersoon het
antiretrovirale behandeling ontvang nie.
METODE: Die intervensie het die daaglikse inname van 40g (200 ml gerekonstitueer)
van óf die toetsproduk óf 'n isokaloriese koolhidraatplasebo gedurende 'n 12 week
periode behels. Antropometriese evaluering (gewig, lengte en trisepsvelvoudikte;
midbo-arm-, middel- en heupomtrekke) is uitgevoer met aanvang en daarna weer
elke 4 weke (4 keer). Biochemiese (serum totale protein, serumalbumien en
C-reaktiewe protein) en hematologiese (volbloedtelling en immunofenotipering)
evaluering is uitgevoer met aanvang en weer na 12 weke.
RESULTATE: Statistiese verwerking van basislyndata is gedoen deur middel van
Wilcoxon twee-steekproef toetse waarmee vergelyking tussen die aangevulde en
plasebogroep uitgevoer is. Studiegevolge is geëvalueer deur verspeidingsanalise
met behulp van Shapiro-Wilk toetse waarna óf paargewyse t-toetse óf tekentoetse
(vir nie-parametriese data) gebruik is. Twee-en-dertig proefpersone het die
studietydperk voltooi, 14 in die aangevulde groep en 18 in die plasebogroep. Gewig
het betekenisvol toegeneem in die aangevulde groep (2.73 ± 3.53 kg, p = 0.013).
Triseps velvoudikte het betekenisvol toegeneem in beide die aangevulde (p = 0.047)
en die plasebogroep (p = 0.001). Geen ander betekenisvolle antropometriese
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veranderinge is waargeneem nie. Serumalbumien het betekenisvol gestyg in die
aangevulde groep (p = 0.003) en het gepaard gegaan met 'n betekenisvolle daling in
C-reaktiewe protein (p = 0.028). Hemoglobienwaardes het in beide groepe
betekenisvol gedaal. 'n Betekenisvolle daling in CD4+ telling is waargeneem in die
plasebogroep terwyl die daling in die aangevulde groep nie betekenisvol was nie.
GEVOLGTREKKING: Mondelingse voedingsaanvulling van 'n beperkte hoeveelheid
was goed aanvaar en verdra oor 'n 3-maande tydperk. Hierdie studie toon dat
'n verrykte voedingsaanvulling in staat is om gewigstoename te bevorder en om
hipoalbumienemie en moontlik ook inflammasie te verlig in volwassenes met
MIVNIGS oor 'n kort tot medium tydperk. Die verrykte voedingsaanvulling blyk nie
'n effek op die immuniteit van mense met MIVNIGS te hê nie. Die klein steekproef
is 'n beperking van die studie en die gevolgtrekkinge is slegs van toepassing op die
toetsproduk as 'n geheel en nie op enige van die onderskeie bestanddele daarvan
nie. Hoewel verdere studies nodig geag word om langtermyn uitvoerbaarheid te
ondersoek, dui hierdie bevindinge daarop dat die gebruik van 'n verrykte
voedingsaanvulling 'n rol speel in die beheer van gewigverlies in persone met
MIVNIGS.
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1CHAPTER 1
INTRODUCTION AND PROBLEM STATEMENT
1.1 MALNUTRITIONAND HIV/AIDS
Sub-Saharan Africa is worst hit by the human immunodeficiency virus (HIV) and
acquired immunodeficiency syndrome (AIDS) pandemic. It is estimated that there
are more than 25 million infected people in this region, accounting for 70% of global
cases.' The majority of these HIV-infected people live in South Africa, where the
prevalence of HIV infection may be as high as 19,2%2, with 40% of adult deaths
being ascribed to acquired immunodeficiency syndrome (AIDS)-related disease."
The impact of HIV/AIDS is felt at all levels of society, in health systems, the
workforce, the economy, and human developrnent.v"
Malnutrition is a common consequence of HIV infection and recent weight loss is
a diagnostic and classification criterion of HIV/AIDS. The relationship between
HIV/AIDS, malnutrition and wasting is cyclic and has been well described in
publications over the last decade or more.6,7,8 Nutritional status is compromised by
reduced and/or inadequate food and nutrient intake9,1o, malabsorption and increased
nutrient losses caused by gastrointestinal dysfunction 11 and increased nutritional
requirements due to infection and fever12,13 (Figure 1.1). Malnutrition by itself is
accepted to contribute to the frequency and severity of opportunistic infections
associated with HIV/AIDS.14 Nutritional status has been identified as a major factor
in survivaI15,16,17 and failure to maintain body cell mass leads to death at 54% of body
mass.18,19
Malnutrition and wasting is a universal consequence of HIV/AIDS. It is documented
that the maintenance of body weight, and in particular lean body tissue, impact
positively on survival in HIV/AIDS.19 In the face of increasing symptoms and
opportunistic infections as the disease progresses, nutritional management of
HIV/AIDS should focus on the support of food and nutrient intake in an effort to
maintain body weight. Documented evidence of the benefit of food-based nutrition
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2intervention in HIV/AIDS is lackinq." The implementation of adjunctive or alternative
nutrition intervention strategies may be required and a great need exists for the
examination of the effects of oral nutritional supplements on nutritional status and
immunity.
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Figure 1.1: The vicious cycle of malnutrition and HIV/AIDS
From: Visser M, Kennedy RD. Patient-centred care: Diet and nutrition. In: Wilson D,
Naidoo S, Bekker L-G, et al. Eds. Handbook of HIV medicine. Cape Town: Oxford University
Press, 2002: 413
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31.2 REVIEWOFNUTRITIONINTERVENTIONSTRATEGIESFORHIV/AIDS
1.2.1 Nutrition counselling
The effectiveness of this nutrition intervention has been documented2o,21 and is
considered paramount to the treatment of HIV/AIDS.22 However, nutrition
counselling and oral nutritional supplementation are generally considered equally
effective in increasing energy intake in malnourished persons with HIV/AIDS.23,24
Nutritional supplements accompanied and augmented by nutrition counselling have
positive effects that manifest as reduction in protein catabolism and repletion of lean
body tissue, but no effect on CD4+ count as a measure of irnrnunlty."
Nutrition intervention for HIV/AIDS that includes intensive counselling supports the
maintenance of not only body weight, but also lean body tissue and the latter effects
may last long after the intervention.25,26 Nutrition supplementation is best
approached as an adjunct to dietary counselling in the nutrition management of
people living with HIV/AIDS.
1.2.2 Nutritional supplements
A small number of studies have evaluated the effects of nutritional supplements on
the nutritional and immune status in people living with HIV/AIDS. The subjects in
these studies were mostly male and all the studies were conducted in the presence
of antiretroviral (ARV) therapy. Due to their small sample sizes and unrepresentative
composition the findings from these studies cannot be generalised.27
In one such study it was possible to achieve weight gain with an energy-providing
supplement enriched with multivitamins and minerals in subjects with severely
depleted immune systems (CD4+ count < 200 cells/rnrrr') at baseline.28 It is however
not possible to distinguish whether the increased energy intake had any effect on
weight gain over and above that of the multivitamins and minerals alone. Nutritional
supplementation with a complete polymeric feed can achieve significant weight gain
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4in people with HIV/AIDS, but it does not have an effect on nutritional status as
measured by serum albumin or immunity as measured by CD4+ and CD8+ counts."
Although it is has been shown that an energy- and protein-rich oral liquid supplement
is of benefit to weight malntenance", adherence to polymeric feeds for HIV/AIDS
wasting is known to suffer with long-term use." Ongoing nutritional supplementation
with polymeric feeds is thus best prescribed in limited quantities to ensure maximum
adherence.
A small number of studies have indicated improved clinical outcomes, but there
exists a paucity of data on the effectiveness of supplemental nutrition on nutritional
status and immunity in HIV/AIDS.8,3o With oral liquid nutritional supplements it is
possible to provide extra energy at times when food intake is compromised.
Energy-providing nutritional supplements, with or without additional nutrients, can
make a meaningful contribution to the care of people living with HIV/AIDS by
supporting body weight. It has not yet been shown that nutrition supplementation
improves immunity or outcome in HIV/AIDS.
1.2.3 Immune-enhancing and specially adapted supplements
Although safe for consumption by persons with HIV/AIDS, evidence for the inclusion
of immunomodulating components in nutritional supplements in this context is not
conclusive.32,33 When immunomodulating components are provided as part of an
energy-supplying nutritional supplement, there is no additional benefit in terms of
weight gain or immunity in HIV/AIDS.34
Supplementation with individual immune-enhancing components, such as
L-glutamine (with which the test product is enhanced) and arginine, has promoted
weight gain35 and improved immunity with increased CD3+ and CD8+ counts and
reduced viral load in HIV-infected people." Glutamine, supplemented together with
antioxidants, is able to increase body weight and body cell mass and is considered
a cost-effective approach to the management of weight loss in HIV/AIDS.37
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5A study investigating an 00-3fatty acid-enriched enterotropic peptide-based formula
showed no change in immunity as measured by peripheral and jejunal mucosal
CD3+, CD4+ and CD8+ counts, although weight remained stable." A later study
involving the same product showed an increase in CD4+ count. 39 Both of these
studies refute an earlier suggestion that enterotropic peptide-based feeds may
provide superior nutritional management in Hlv-intection." Specially adapted,
semi-elemental oral supplements may however be of benefit in patients with chronic
malabsorption due to HIV/AIDS.41 Supplementation with fish oil containing 00-3fatty
acids produces a weak anticytokine action, but it is not able to overcome the
metabolic and nutritional consequences of HIV/AIDS.42
The results are conflicting and the most recent study concluded that neither standard
nor immune-enhancing formulas had any significant effect on nutritional status or
immunity with HIV/AIDS.32 The latter study was conducted in the presence of ARV
therapy, which does not apply to the current South African HIV/AIDS scenario and
may have diminished the effectiveness of immunonutrition. The study was not
blinded and with a small sample size (3 groups comprising 19, 26 and 21 subjects
each completed the study) it may not have been possible to detect minor therapeutic
effects. A serious limitation of this study is the lack of a true control group, since all
the subjects received dietary counselling, which could have lead to change in
background dietary behaviour. Substance abuse, associated with immune
suppression, was not excluded from the sample and may have rendered the sample
unresponsive to immunonutrition. There exists a definite need for more research into
immunonutrition in people living with HIV/AIDS, particularly in the absence of ARV
therapy, which was not freely available in South Africa at the time of the study.
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61.3 RATIONALE FOR THE TEST PRODUCT
1.3.1 Description of the product
The product under investigation (Appendix 1) is a soya-based liquid supplement.
Based on scientific evidence, not always pertaining to people living with HIV/AIDS,
the manufacturer enriched the test product to include multiple micronutrients
(Appendix 2) to address known nutritional deficiencies associated with HIV/AIDS and
to support the immune system. The minerals are amino acid chelated for improved
absorption. It is also enriched with L-glutamine, and prebiotics (Appendix 3) and
probiotics.
The manufacturer recommends an intake of one feed per day that consists of one
sachet (40g of dry powder) mixed with 200 ml of cold water. Due to its food-based
macronutrient content the product supplements the diet with energy (663 kJ/d) and
protein (6.9 g/d). The efficacy of the test product has not been tested but, on the
basis of available evidence, it may be helpful in addressing HIV/AIDS wasting,
particularly in populations with marginal or reduced energy intake, and it may
enhance immune function.
1.3.2 Cost benefits of the test product
The recommended price of this product competes very well with nutritional
supplements marketed by the pharmaceutical industry. Medical aid schemes in
South Africa do not cover the costs of nutritional supplements that are often required
in the management of chronic debilitating conditions, which include HIV/AIDS. The
availability of low-cost nutritional supplements offers the possibility of affordable
nutrition support to people living with HIV/AIDS in resource-limited surroundings. By
enriching such supplements with nutrients and other dietary components, which may
support the immune system, the potential exists for added health benefits. This
product is well positioned in the marketplace to make it affordable not only for use in
home-based care, but also accessible to HIV/AIDS supporting NGOs wishing to
include nutritional supplements in food parcels for people living with HIV/AIDS.
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71.3.3 Possible health benefits of the test product
1.3.3.1 Benefits of micronutrient enrichment
Micronutrient deficiencies have often been reported with HIV/AIDS7,43 and
accelerated disease progression and increased morbidity and mortality are
associated with such deficiencies.44,45 A number of studies have reported
a deceleration of HIV/AIDS disease progression with micronutrient
supplementation.43,46,47 Current information suggests that multi-micronutrient
supplementation for decelerating disease progression may be more beneficial than
single nutrients." The test product is enriched with multivitamins to 100% and
minerals to 15% of the 1989 recommended dietary allowance (RDA) for adults
provided in one portion per day. Higher levels of vitamin A and zinc supplementation
in particular are associated with accelerated progression of HIV/AIDS and should be
avoided.48,49
Due to its micronutrient content the test product has the potential to address
micronutrient deficiencies associated with HIV/AIDS. The benefits may be seen in
terms of improvement of parameters of nutritional anaemias commonly found with
HIV/AIDS and may also be evident in terms of improved immunity, which is
associated with a number of micronutrients, in particular vitamin A, selenium and
zinc.
1.3.3.2 Benefits of glutamine enrichment
Glutamine, usually a non-essential amino acid, has been reclassified as "conditionally
essential" in catabolic stress situations such as trauma and sepsis. It serves as fuel
for the growth and proliferation of the cells of the intestinal mucosa and is important
to enhance absorption, which is impaired with HIV/AIDS. Glutamine supplementation
in animals has been shown to be involved in the maintenance of intestinal mucosal
integrity resulting in improved barrier function to prevent the translocation of
pathogens.50,51,52 In humans parenteral glutamine supplementation is safe, maintains
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8intestinal permeability and leads to improved nitrogen balance and clinical outcome
after surgery. 53
HIV/AIDS is associated with glutamine deficiency", impaired intestinal integrity and
increased gut permeabllity." The benefits of glutamine as a single nutrient
supplement in people living with HIV/AIDS have been described in terms of
enhanced absorption", weight gain and improved trnmunlty."
In the area of critical care, from which most of the supporting evidence originates,
glutamine supplementation is still debatable after many years of research. Minimal
information is available for HIV/AIDS where glutamine supplementation does not
seem to outweigh the benefits of energy supplementation" It is thus suggested that
glutamine is best provided as part of an enriched nutritional supplement for HIV/AIDS
rather than an isolated nutrient, as is the case with the test product.
1.3.3.3 Benefits of probiotic enrichment
Based on evidence of their viability in the human gut, the test product is enriched with
the probiotic microorganisms Lactobacillus acidophilus and Bifidobacterium bifidus.56
Probiotics playa role in aiding absorption and synthesising micronutrients to the
benefit of the host and also stabilise the luminal environment, whereby it contributes
to preventing bacterial diarrhoeal disease.58.67 In this regard probiotics have also
been found beneficial in the treatment of HIV/AIDS-associated dlarrhoea."
Bifidobacterium is considered safe for human consumption6o.61 and Lactobacillus
provides a favourable environment for its proliferation.
The ability of probiotics to influence the intestinally based immune system by
stimulating the gut-associated lymphoid tissue (GALT) has recently been the focus of
increasing scientific attention." Lactobacillus has been reported to enhance the
natural immunity of the gUt.62 Probiotics have also been reported to lead to increased
numbers of circulating white blood cells and may influence immunity by stimulating
the production of certain cytokines, which are involved in T-cell producnon." One
large study (n > 4000) reported a possible direct inhibitory effect of probiotics on HIV
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9infection in women, but prudently warns the reader against cause-and-effect
conclusions."
Although little information is available on the role of probiotics in HIV/AIDS in
particular, there is no reason to believe that their reported benefits will not apply to
people living with HIV/AIDS where malabsorption and diarrhoea are common
intestinal disorders. There is also particular interest in the possible benefits that
probiotics may offer in terms of immunity.
1.3.3.4 Benefits of prebiotic enrichment
Prebiotics are non-digestible oligosaccharides including inulin and oligofructose,
which, by resisting digestion in the small bowel, are available for bacterial
fermentation in the colon. This fermentation process produces short-chain fatty
acids, which are hypothesised to be involved in the mechanism underlying the
immunomodulating effect of prebiotics. Other possible mechanisms are the direct
contact of probiotic bacteria, their proliferation stimulated by prebiotics, with the
immune cells in the intestine, and modulation of mucin production."
Preliminary data from animal studies suggest that prebiotics are able to modulate
immune parameters in GALT, secondary lymphoid tissue and peripheral blood. This
is a relatively new area of investigation and the immune-modulating effect of
prebiotics is generally attributed to its ability to selectively modify the gut flora.65,66,67
As such it is considered an essential adjunct to the probiotics contained in the test
product.
To move beyond this limited perception of prebiotics in synbiosis with the gut flora,
further research is required to explore the immune-enhancing effect of prebiotics per
se. Nearly all the studies investigating the effects of prebiotics on immunity were
based on animal models and it is not possible to draw conclusions on the immune
effects of various dietary fibres in humans. Human studies are of course limited by
the fact that peripheral blood parameters are mostly used for immune assessment,
while it is recognised that immunity may be affected at various sites in the body,
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which are not practical for assessment.
1.4 SIGNIFICANCEOF THE STUDY
The evaluation of effective, affordable and acceptable nutrition interventions is
particularly important in South Africa where ARV therapy, available in the
industrialised world, still remains unaffordable and inaccessible to most people living
with HIV/AIDS. Although effective in decreasing HIV/AIDS-related mortality and
morbidity, ARV therapy does not eliminate the wasting seen with HIV/AIDS68 and
therefore does not diminish the role of nutrition intervention. All studies published to
date have investigated nutritional supplementation as an adjunct to ARV therapy,
including protease inhibitors. It is not possible to distinguish between the effect of
ARV therapy and nutrition supplementation in these studies. In contrast, this pilot
study is unique in that it investigated the effects of nutritional supplementation in
HIV/AIDS without the benefit of ARV therapy.
Most previous studies were performed in the United States of America and a smaller
number in Europe. No study on oral nutritional supplementation in Africa or other
developing parts of the world has thus far been published. Only one prospective,
longitudinal study was previously attempted in South Africa on the effectiveness of
supplemental feeding in persons with HIV/AIDS not receiving ARV therapy." The
study was curtailed by a poor follow-up rate, possibly related to the stigma attached
to HIV/AIDS, which rendered the results inconclusive. The results of the pilot study
presented here therefore contributes not only to the care of people living with
HIV/AIDS in South Africa, but also to the relatively small body of information on the
subject internationally.
This independent research was commissioned by the manufacturer as part of its
research and development programme of a new product. Appendices 1 and 2
provide the composition of the product. The results of this study will be of direct
benefit to the manufacturer in the marketing and development of their product.
Considering the possible effects of HIV/AIDS on expendable income and household
food security, it is important to scientifically ascertain the effectiveness of any new
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product before health claims are made.
1.5 STUDY AIMS
The primary aim of this pilot study was to investigate the effects of a multiple
micronutrient, glutamine and pre- and pro-biotic enriched liquid supplement on the:
1 nutritional status of people living with HIV/AIDS by means of anthropometric
and biochemical assessment over a period of 12 weeks.
2 immunity of people living with HIV/AIDS by means of CD3+, CD4+ and
CD8+ counts and their ratios over a period of 12 weeks.
1.6 HYPOTHESIS
It was hypothesised that the test feed would have no effect on either the nutritional
status or the immunity of people living with HIV/AIDS.
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CHAPTER2
METHODOLOGY
2.1 STUDY DESIGNAND ETHICS
2.1.1 Type of study
The study was designed as a prospective, randomised, double-blind, placebo-
controlled clinical trial. The research project was registered as a pilot study.
2.1.2 Ethical considerations
A research protocol (Appendix 4) for this pilot study was submitted to and approved
(Ref No 2002/C/102) by the ethics committee of the Health Science Faculty of the
University of Stellenbosch, Tygerberg, South Africa. Confidentiality was ensured
throughout the study process.
All costs incurred in the execution of the study were covered by a grant from the
manufacturers of the supplement, African Dynamics Pty (Ltd), Pretoria, South Africa,
and did not include incentives for subjects or remuneration for the researcher or staff
involved in the study.
2.1.3 Intervention
2.1.3.1 Test product and placebo
The subjects were required to consume a single portion per day of either the test
product, B-imune® (African Dynamics), or a placebo for a period of 12 weeks. One
sachet (40g) of dry product mixed with 200 ml of cold water constituted one portion.
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Each subject was provided with a calibrated mixer container to standardise
preparation of the product. The mixing procedure was physically demonstrated
during the baseline visit.
One portion of the test product (Appendices 1 and 2) provided 663 kJ, 6.9 g protein
and was enriched with vitamins, minerals, L-glutamine, and pre- and probiotics. The
placebo (Appendix 5) was developed to match the test product in volume, taste,
colour and consistency. It contained 655 kJ of energy, but was devoid of the
enrichment provided in the test product. Maltodextrin was used to expand the bulk of
the dry placebo to match the test product. An energy-empty placebo constituted very
low dry volume and did allow for identical packaging required for blinding.
2.1.3.2 Assessment and follow-up
Baseline data was collected and the subjects were followed up every 4 weeks until
completion of the study after 12-weeks of intervention. Anthropometric assessment
was performed at baseline and each of the three follow-ups, while biochemical and
haematological assessment occurred only at baseline and at week 12 (Figure 2.1).
The supplement or placebo was distributed to the subjects in 4-week supply parcels
distributed at baseline and again at week 4 and week 8 of the study period. In the
event where subjects were unable to attend follow-ups, volunteer workers from the
hospice delivered the parcels to their homes.
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2.1.4 Randomisation and blinding
TEST PRODUCT
AND PLACEBO
PREPARATION
Figure 2.1: Flow diagram of the research study
A 12-week supply of 25 sets each of the test product and the placebo was prepared
by the manufacturer in indistinguishable, unlabeled packaging. The manufacturer
randomised the sets by lottery and retained exclusive access to the feed identification
code. The identification code was broken only after completion of the study. The 50
randomised sets were delivered to the researcher in a single batch with consecutive
numbering. Each set was divided into three 4-week supply parcels for convenience
of distribution at baseline and weeks 4 and 8 follow-up visits. Study numbers were
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consecutively allotted to subjects upon entry to the study and matched with the
identically numbered pre-randomised supply parcels. Both the subjects and the
researcher were blinded to the identity of the feeds. Each subject received an
identification card (Appendix 5) containing only his/her study number and
appointments for follow-up visits.
2.2 SAMPLINGAND INDUCTION
2.2.1 Sampling method
A sample of 50 volunteers was recruited among ambulatory, disclosed HIV-infected
adult clients (> 18y and < 60y) attending the community-based Moreteie Sunrise
Hospice at Hammanskraal in the North-West Province of South Africa, 50 km north of
Pretoria. Provided they met the inclusion criteria, all the clients of the hospice were
invited to participate in the study. No limitation was placed on the number of
volunteers at entry, and after active recruitment by hospice staff and volunteer
community workers, this initial number represented exhaustion of the available
ambulatory client base of the hospice at the time the study was initiated. The
subjects routinely visit the hospice once per week, which enabled induction of the
sample over two sessions, one week apart, to accommodate time and laboratory
constraints.
2.2.2 Selection criteria
HIV infection was the primary inclusion criterion for this study. Clients are referred to
the hospice with written notification of their HIV status after testing positive at
surrounding community clinics operated by the provincial health service. Re-testing
for confirmation of HIV status was not considered necessary for this study. Subjects
were included regardless of duration or stage of HIV infection and none of the
subjects received ARV treatment or reported taking any other nutritional
supplements. The age range for inclusion was from 18 to 60 years. Pregnant
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women, and volunteers who were too weak to participate fully in the trial, were not
included.
2.2.3 Written consent
A research assistant proficient in the local languages assisted the subjects with
completion of a written consent form (Appendix 6) and each subject received a
personal identification and appointment card (Appendix 7). All procedures and
requirements were explained in either English or the subject's home language and
none of the subjects eligible for entry into the study refused consent. To enable the
researcher to trace the subjects by study number, minimal personal information was
collected. Only the researcher had access to the subject information records to
ensure confidentiality (Appendix 8) and alone was able to identify and trace the
subjects when necessary.
2.2.4 Instructions to subjects
Besides instructions for the mixing of the product and consumption of a single portion
once daily of either the test product or placebo as prescribed, subjects were advised
to continue with their usual routine and were requested to report initiation of other
nutritional or immune-enhancing supplements during the study period. A signed
distribution record (Appendix 9) was kept for baseline and the first two follow-up visits
during which distribution took place. Subjects were provided with 28-day supplement
consumption record diaries (Appendix 10) between follow-up visits and were required
to return the completed records. The research dietitian used the returned intake
records to monitor consumption during follow-up visits. Subjects were provided with
contact details of both the researcher and the research assistant and requested to
report any problem encountered with the research protocol. Because many subjects
do not have access to telephones they were also encouraged to communicate via the
support staff of the hospice, with whom they were familiar.
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2.3 DATA COLLECTION
2.3.1 Anthropometry
An experienced registered dietitian performed all anthropometric assessments using
standard procedures'? at baseline and week 4, 8 and 12 follow-up visits. All
measurements were performed twice, the average recorded and the process
repeated in the case of discrepancies. Height, weight, triceps skinfold thickness
(TSF) and mid-upper arm (MUAC), waist and hip circumferences were measured.
A Seca® balance-beam scale with stadiometer was used to measure height to the
nearest 0.5 cm and weight to the nearest 0.1 kg. Subjects were measured and
weighed in one light layer of outer clothing, with shoes and headdress removed, and
all measurements were performed between 10hOOand 12hOOto control for circadian
variation. The study was completed during the warm summer months and similar
clothing was evident throughout. Height measurement was done with the subject
standing with feet together, upright and the head placed in the Frankfort plane." The
scale was regularly controlled for zero reading between measurements.
Plastic skinfold calipers (Slim Guide", Creative Health Products, Plymouth, Michigan,
USA) were used to measure TSF to the nearest 0.5 mm on the right or dominant arm
with the arm relaxed and extended to the side. The mid-acromial-radiallevel was
measured and marked and TSF and MUAC were measured at this level. MUAC was
measured on the exposed, relaxed arm along a horizontal plane at the marked level,
the tape being pulled taught without exerting pressure.
Waist and hip circumferences were measured in the horizontal plane with the tape
pulled tight over light clothing, but not causing indentation. Waist circumference was
measured at the midpoint between the lower costal border and iliac crest, arms at
side. Hip circumference was measured at the widest point of the posterior (gluteal)
protuberance, feet together and gluteal muscle relaxed. An automatically retractable
fibreglass tape was used to measure all circumferences.
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2.3.2 Biochemistry
A registered nursing professional collected venous blood samples according to the
specimen collection protocol (Appendix 11) using 5 ml capacity vacuum tubes without
anticoagulant treatment (BO Vacutalner", Preanalytical Solutions, Plymouth, UK), at
baseline and at the end of week 12. The specimens were immediately refrigerated
and coagulated blood samples were delivered to the laboratories of the Department
of Chemical Pathology, Medical University of South Africa (Medunsa), in insulated,
covered containers within 4 hours of collection. Same-day centrifugion and
harvesting and freezing of the serum were performed. Frozen baseline samples
were stored at -120 C for a maximum of three weeks for batch analysis, the time it
took to complete each of the baseline and 12-week follow-up specimen batch
collections.
All instruments were calibrated according to manufacturer's procedures and all
relevant quality control measures with Decision" Liquid Comprehensive Chemistry
Control Serum (Beckman Coulter, Fullerton, CA, USA) were within limits
(~ ± 2SD). Routine 2-hourly Decision" Level 2 and Level 3 controls are run at this
National Health Laboratories Services facility. Additional dedicated Decision" Level2
controls were implemented for each batch analysis of this pilot study. Serum total
protein (s-TP) concentration was determined by means of a rate biuret method.
Serum albumin (s-Alb) concentration was measured with a timed endpoint method
using albumin reagent. In the reaction, albumin combines with bromine cresol purple
(BCP) dye to form a coloured product. Both s-TP and s-Alb were measured with the
Synchron c:x® 7 Delta (Beckman Coulter). C-reactive protein (CRP) was measured
with the Immage® Immunochemistry System (Beckman Coulter) that utilises rate
nephelometry to measure the rate of increase in light scattered from particles, the
result of complexes formed during an antigen-antibody reaction, suspended in
solution.
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2.3.3 Haematology
A registered nursing professional collected venous blood samples according to the
specimen collection protocol (Appendix 11) using 4 ml capacity anticoagulant-treated
(7.2 mg K2EDTA) vacuum tubes (BO Vacutalner") at baseline and at the end of
week 12. Taking account of circadian variability, specimen collection occurred
according to a specimen collection protocol (Appendix 10) within the same 2-hour
window period on both occasions. Blood samples were immediately refrigerated and
delivered to the laboratories of the Department of Haematology, Medunsa, in an
insulated, covered container within 4 hours of collection where same-day analyses
were performed.
Full blood counts (FBC) were performed on an Advia" 120 (Bayer Corporation,
Diagnostics Division, Tarrytown, NY, USA) automatic haematology analyser which
analyses 100 ~I of whole blood and provides results within one minute. Calibration
was performed according to manufacturer's procedures and regular external quality
control procedures of NHLS.
Immunophenotyping was performed with a Beckman Coulter XL®desktop flow
cytometer (Beckman Coulter), flow cytometry being the method of choice for
CD4+ monitoring in HIV/AIDS.72 Specimens were treated with Q-Prep® (Beckman
Coulter) solution, which lyses red blood cells and fixes the membranes of white blood
cells. Thereafter 10 000 lymphocytes were automatically analysed for CD3+,
CD4+ and CD8+ subsets. The results were printed in numeric and graphic form,
providing absolute values for CD4+ and CD8+; CD3+ percentage; and CD3+: CD4+,
CD3+: CD8+ and CD4+: CD8+ ratios.
Internal quality control measures are performed according to manufacturer's
(Beckman Coulter) procedures with their Flowcheck® laser lamp alignment procedure
twice daily and Immunotrol® test kit which controls results on a test specimen as part
of an international quality assurance programme. External quality control procedures
are regularly performed with Immunotrol® in conjunction with a 19-centre NHLS pilot
project. All relevant quality control measures were within limits (~ ± 2SD).
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2.4 STATISTICS
2.4.1 Calculationof derivedparameters
Derived parameters were calculated using the following standard formulas:71,73
Body mass index (BMI) (kg/m2):
w(kg)
height(m)2
Relative body weight (RBW) (%):
actual body weight x 100
reference weight
Waist:hip ratio (WHR):
waist circumference
hip circumference
Mid-upper arm muscle circumference (MAMC) (em):
MUAC - (n x TSF)
Mid-upper arm muscle area (MAMA) (crrr'):
[MUAC - (n x TSF)]2
nx4
Bone-free mid-upper arm muscle area (BMAMA) (ern"):
Females:
Males:
MAMA - 6.5 cm2 (females)
MAMA - 10 cm2 (males)
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2.4.2 Statisticalanalysis
Data was captured electronically with Microsoft Excel® and controlled for precision of
data transfer with regular cross-referencing. The University of Stellenbosch
appointed a consultant statistician to assist with data analysis using SAS System for
Windows®, Release 8.02 (SAS Institute Inc., Cary, 111.,USA). Means (~and
standard deviations (SO) were calculated for all parameters. Baseline data for the
supplemented and placebo groups were compared with the two-sided Wilcoxon
two-sample test. A pairwise t-test was used to compare baseline and final
follow-up data. Normality of distribution was tested with Shapiro-Wilk tests and
nonparametric tests were performed with the sign test. McNemar tests were used to
compare prevalence of malnutrition before and after intervention. The level of
significance was set at p < 0.05 and applied to all tests.
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CHAPTER 3
RESULTS
3.1 SAMPLE CHARACTERISTICS
3.1.1 Sample description
Twenty-six and 24 volunteers were recruited during the first and second induction
sessions respectively, one week apart. Of the 50 volunteers recruited, 47 subjects
were included at baseline (Table 3.1), after exclusions for pregnancy (2) and
advanced HIV/AIDS progression (1) where neurological complications rendered the
volunteer incapable of full participation and it was considered unethical to subject the
volunteer to the rigours of the study. The pre-randomised feed allocation placed 22
subjects in the supplemented group and 25 in the placebo group. The research site
is located in a historically black settlement area and all the subjects were black, with
an age range of 19 to 56 years (31.62 y ± 7.94). The subjects had been aware of
their HIV status for anything from 4 months to 7 years (2.29 y ± 1.82). No reliable
information was available for duration of HIV infection and the lack of clinical data in
the community-based setting of this pilot study renders specified CDC disease stage
classification 74 impractical.
3.1.2 Sample retention and drop-out
During the first follow-up visit (week 4) 42 subjects (89%) returned while 5 subjects
were absent due to employment commitments (2), relocation (1) and lost contact (2).
At the second follow-up (week 8) 32 subjects (68%) returned, one subject had
deceased, one was too weak to attend, 2 had work obligations and 6 were
unaccounted for. Subjects who missed follow-ups had their feed parcels delivered to
their homes and the intake records of the previous 4 weeks were collected where
possible. During the home visits it became apparent that these subjects had
experienced disease progression or secondary disease, which contributed to their
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inability to attend previous follow-ups. During subsequent follow-up visits the
research dietitian interviewed returning subjects regarding compliance. No subject
voluntarily requested discontinuation.
The third and final follow-up (week 12) also included 32 subjects (68%). Baseline
and final 12-week follow-up data was available for 32 of the original 47 subjects. This
total final sample, which completed the 12-week trial, comprised 14 subjects in the
supplemented group and 18 subjects in the placebo group. It is for these 32 subjects
that baseline and 12-week comparison is reported. The 27 (84%) female subjects
constituted a majority, with only 5 (16%) males included in the trial.
3.1.3 Intervention tolerance and compliance
Blinding remained intact throughout the follow-up period and in only one case of a
cohabiting couple, belonging to both groups respectively, was suspicion about the
"supplement" reported. The majority of subjects initially returned their intake records
(37 of 42 at week 4; 17 from the supplemented group and 20 from the placebo
group), but this tapered off with the second follow-up visit (20 of 32 at week 8;
11 from the supplemented group and 9 from the placebo group) and even more so
with the final follow-up visit (12 of 32 at week 12; 8 from the supplemented group and
4 from the placebo group). Excellent compliance with the dietary intervention was
reported in the returned records. Both the test product and placebo were well
accepted by the subjects and no-one reported discontinuation due to the nature of
the intervention. The few ailments reported over the 12-week period included
nausea (1 in supplemented group), vomiting (2 in supplemented group), diarrhoea
(2 in each group), constipation (1 in placebo group), abdominal pain (2 in each
group), tonsillitis (1 in placebo group) and unexplained fever (1 in placebo group).
None of these were reported to be directly associated with the intervention and on
the converse two subjects reported "feeling better" and two having improved appetite,
all from the supplemented group. Too few data were obtained from the intake
records to warrant analysis, and no conclusion can be drawn in terms of clinical
outcomes. A low educational level and illiteracy in this community contributed to the
lack of adequate information provided on the appearance of symptoms. No subject
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at any time reported taking nutritional supplements other than the intervention
required for this trial.
3.2 BASELINE DATA
3.2.1 Baseline group comparison
Baseline values (Table 3.1) were compared with the two-sided Wilcoxon two-sample
test and indicated that the two groups in this convenience sample were well matched.
MCHC (p = 0.027) was the only variable found to be significantly different between
the groups. The CD8+ count for one subject in the placebo group diverted more than
+28D from the mean and was excluded. This exclusion did not affect the mean
significantly and the subject was referred the local hospital for further clinical
assessment.
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Table 3.1: Baseline characteristics of the subjects in the study (n = 47)
Variables Reference Supplemented Placebo Total
values group group sample
and units x (%) orx± SO x (%) orx±SO x (%) or x ± SO
n - 22 (47) 258 (53) 47°
Female (F) - 20 (43) 19(40) 39 (83)
Male (M) - 2 (4) 6 (13) 8 (17)
Age y 32.05 ± 7.32 31.25 ± 8.59 31.62 ± 7.94
Known duration y 2.56 ± 2.14 2.06 ± 1.50 2.29 ± 1.82
of HIV+ status
Height m 159.41 ± 7.98 160.34 ± 6.73 159.90 ± 7.28
Weight kg 51.06 + 12.88 53.30 ± 10.95 52.25 ± 4.93
BMI >18kg/m"' 19.98 ± 4.29 21.37 ± 5.43 20.72 ± 4.50
TSFo 16.5(F), 12.5(M) 10.34 ± 5.69 10.04 ± 6.12 10.18 ± 5.86
mm
MUACa 23.2(F), 25.3(M) 24.11 ± 4.5 25.54 ± 4.55 25.26 ± 4.36
cm
MAMC cm 21.69 ± 2.73 22.39 ± 3.41 22.06 ± 3.10
MAMA cm" 37.98 ± 9.55 40.75 ± 12.13 39.45 ± 10.97
BMAMA cm"' 31.16 ± 9.50 33.41 ± 12.05 32.35 ± 10.88
Waist cm 72.93 + 9.97 73.30 + 8.21 73.14 ± 8.97
Hip cm 89.48 ± 11.02 92.04 ± 13.05 90.84 ± 12.08
WHR 0.8 (F); 1.0 (M) 0.82 + 0.05 0.80 ± 0.06 0.81 ± 0.06
s-TP 64 - 84 gil 90.32 ± 9.16 94.46 ± 16.80 92.48 ± 13.70
s-Alb 35 - 52 gil 31.96 ± 7.77 31.00 ± 7.69 31.46 ± 7.66
CRP < 10 gil 13.18 + 15.25 18.61 + 31.40 16.01. ± 24.90
WBC 4.8 - 10.8 x10\i/IJI 6.76 ± 5.68 4.32 ± 1.58 5.50 ± 4.08
RBC 4.2 - 6.1 x10 ILlIJl 3.75 + 0.68 3.64 ± 0.74 3.77 ± 0.63
Hb 12 - 18 gldl 11.27 ± 2.39 10.98 ± 2.60 11.37 ± 2.33
MCV 80-99fl 87.71 ± 6.41 87.40 ± 7.27 87.54 ± 6.80
MCH 27 - 31 pg 29.74 ± 3.19 30.01 ± 2.87 29.88 ± 3.00
MCHCe 33 - 37 gldl 33.26 ± 1.05 34.00 ± 2.01 33.65 ± 1.65
Lymphocytes 0.9 - 5.2 x10"/1J1 2.66 + 4.19 1.43 + 0.94 1.93 ± 2.43
CD3+ 65 - 91% 76.27 ± 10.21 71.88 ± 13.86 73.98 ± 11.58
CD4+ 500 - 1500/mm"' 268.36 ± 216.70 212.88 ± 12.55 228.94 ± 213.25
CD8+ 230 - 800/mm"' 806.78 ± 373.90 696.50 ± 600.33c 747.96 ± 513.27c
CD3+: CD4+ 30 - 65% 14.86 ± 9.38 13.70 ± 11.18 14.26 ± 20.26
CD3+: CD8+ 17 - 35% 55.24 + 10.21 53.29 + 14.86 54.20 ± 12.80
CD4+: CD8+ 1.0 - 3.5:1 0.31 ± 0.23 0.32 ± 0.41 0.31 ± 0.34
8 Biochemical and haematological assessment for n = 24 only, one set of baseline blood
specimens lost.
b Biochemical and haematological assessment for n = 46 only, one set of baseline blood
specimens lost.
c One divergent value (> +2S0) excluded.
d WHO reference values.
e Significant difference between groups (p = 0.027) with Wilcoxon two-sample test.
Abbreviations: BMI = body mass index, TSF = triceps skinfold thickness, MUAC = mid-upper
arm circumference, MAMC = mid-upper arm muscle circumference, MAMA = mid-upper arm
muscle area, BMAMA = bone-free mid-upper arm muscle area, WHR = waist/hip ratio,
s-TP = serum total protein, s-Alb = serum albumin, CRP = C-reactive protein,
Hb = haemoglobin, MCV = mean corpuscular volume, MCH = mean corpuscular haemoglobin,
MCHC = mean corpuscular haemoglobin concentration.
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3.2.2 Evaluation of baseline nutritional status and immunity
Although unexplained weight loss of 10% is a diagnostic criterion for HIV/AIDS, the
subjects were not routinely monitored and no data was available for weight loss prior
to the study. To assess body weight at baseline, Relative Body Weight (RBWl1 was
calculated using the lower limit of the mid-range (25th percentile) of sex-, age- and
race-specific reference values" as reference weight, which roughly corresponds with
BMI of 20 to 22. Low body weight (RBW < 90%) was present in 67% (14) of the
subjects/volunteers in the supplemented group (2S= 87%) and 58% (14) of the
placebo group (2S= 88%). Overweight (RBW > 120%) was present in only one
subject in each of the two groups. Using BMI < 18 kg/m2 as diagnostic indicator for
undernutrition, 41% (9) of the supplemented group and 16% (4) of the placebo group
were underweight. Two subjects, one from each group, for whom date of birth were
not available, were excluded from age-specific evaluations. Although all subjects had
WHR within the reference range, this was not used to assess nutritional status at
baseline but to detect redistribution of body fat at the end of the study.
TSF was evaluated with sex, age and race specific reference values." Values below
the s" percentile were indicative of malnutrition in 38% (8) of the supplemented
group and 29% (7) of the placebo group. MUAC below the sex and age specific
5th percentile " was found in 38% (8) of the supplemented group and 42% (10) of the
placebo group. For comparison with other studies, WHO reference values" were
also employed, and percentage of reference values was calculated for TSF and
MUAC at baseline. These evaluations produced higher malnutrition prevalence
figures with 85% (18) of the supplemented group and 80% (19) of the placebo group
below the respective TSF reference values. For MUAC 43% (9) of the supplemented
group and 38% (9) of the placebo group, were below the WHO reference value.
Expressed as a percentage of the WHO standard, mean TSF was well below
standard for both the supplemented and placebo group at 59% and 64%
respectively. MUAC was slightly above the WHO reference with mean percentage of
standard reaching 108 in the supplemented group and 109 in the placebo group.
The difference in results of TSF and MUAC evaluation indicate that the arm
circumference remained intact relative to the apparent subcutaneous fat depletion in
the sample.
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Baseline mean s-Alb below the reference range « 35 gIl), traditionally considered an
indicator of malnutrition, for both groups was indicative of chronic inflammation, which
was present equally in 52% (11) of the supplemented group and 52% (13) of the
placebo group. Elevated mean CRP > 10 gIl indicated the presence of inflammation
and the possibility of acute infection in both groups, in 33% (7) of the supplemented
group and 32% (8) of the placebo group. Mean total lymphocyte count, an indicator
of both nutritional status and immunity, was within the reference range for both
groups. In 28% (13) of the sample, representing 19% (4) of the supplemented group
and 36% (9) of the placebo group, total lymphocyte counts were below the reference
range when assessed individually.
Anaemia (females, Hb < 12 g/dl; males, Hb < 13 g/dlf8 was common at 76% (16) in
the supplemented group and 52% (13) in the placebo group. White blood cell counts
were within or near the reference range, but red blood cell counts were decreased in
both groups. Hypochromic, microcytic anaemia was present in 8 (38%) subjects in
the supplemented group and 6 (24%) in the placebo group. Macrocytic anaemia
occurred in 5 (24%) subjects in the supplemented group and 5 (20%) in the placebo
group.
Nearly all the subjects were immuno-compromised with only 5 having CD4+ counts
within the reference range. Severely depleted (CDC 1993)74 CD4+ counts < 200
cells/rnrrr' occurred in almost half (47%; 21 subjects) of the total sample at baseline,
specifically in 43% (9) of the supplemented group and 52% (13) of the placebo
group. Further indicative of poor prognosis, mean CD4+: CD8+ ratio was also
substantially below the reference range in both groups.
The sample was at an advanced stage of HIVIAIDS disease progression with nearly
half of the subjects having AIDS-defined disease." No significant difference existed
for immunity parameters between the two groups at baseline (Table 3.1), yet a
greater proportion of subjects in the placebo group had clinically advanced HIVlAIDS.
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3.3 STUDYOUTCOMESIN TERMSOFOBJECTIVES
3.3.1 Nutritional status outcomes
3.3.1.1 Outcomes in the supplemented and placebo groups
Only the data for the 32 subjects who completed the study period were used for
comparative outcomes analysis. Shapiro-Wilk tests with normality established at
p < 0.05, indicated normally distributed data in most of the variables. This implies
that the t-test, valid for small samples from normal populations in the presence of
equality of variance, could be used to compare change within and between the
groups. Pairwise t-test comparison between baseline and final 12-week follow-up
data within the supplemented and placebo groups respectively indicated that change
occurred in all variables though few changes were statistically significant (p < 0.05)
(Table 3.2).
Among the anthropometric parameters weight increased significantly by
2.73 ± 3.53 kg (p = 0.013) in the supplemented group while a non-significant weight
loss of 0.27 ± 5.05 kg occurred in the placebo group (Figure 3.1). Change in body
weight did not result in significant change in BMI in either group. TSF increased
significantly by 0.89 ± 1.52 mm (p = 0.047) in the supplemented group and similarly
by 0.88 ± 1.56 mm (p = 0.001) in the placebo group (Figure 3.2). No significant
change was observed in either group for any other anthropometric parameter.
In the supplemented group s-Alb increased significantly by 2.50 ± 3.92 gIl (p = 0.033)
compared to an insignificant decline in s-Alb in the placebo group (Figure 3.3). In
contrast to the insignificant increase in CRP in the placebo group, CRP declined
significantly by 8.04 ± 12.56 gIl (p = 0.028) in the supplemented group (Figure 3.4).
The baseline anaemia worsened with a decline in Hb by 0.56 ± 0.95 gIl (p = 0.047) in
the supplemented group and 0.95 ± 1.26 gldl (p = 0.007) in the placebo group. MCH
and MCHC decreased significantly by 2.19 ± 3.04 pg (p = 0.024) and 1.16 ± 1.15 gldl
(p = 0.002) respectively in the supplemented group and similarly by 1.87 ± 1.40 pg
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(p < 0.0001) and 1.93 ± 1.44 g/dl (p < 0.0001) respectively in the placebo group.
Neutrophils decreased significantly by 0.94 ± 1.50 x 109/1J1(p = 0.036) in the
supplemented group, whereas in the placebo group there was no significantly
significant change, but monocytes decreased significantly by 0.07 ± 0.68 x 109/1J1
(p = 0.001) (not shown in table).
Table 3.2: Comparison of nutritional status at baseline and 12-week
follow-up visit (n = 32)
Supplemented group Placebo group
Reference n = 14 n = 188
Parameters values x+ SO x± SO
and units Baseline Week 12 Change Baseline Week 12 Change
Weight kg 49.19 51.92 2.73° 54.39 54.13 - 0.27
± 13.77 + 13.97 +3.53 ± 6.28 ± 8.63 ± 5.05
BMI > 18 kg/m;': 19.26 20.27 1.02 22.04 21.17 - 0.87
± 4.74 ±4.67 ± 1.40 ±4.02 ± 3.40 ± 3.09
TSF mm 8.71 9.61 0.89D 10.97 11.86 0.88°
± 5.71 ± 5.86 ± 1.52 ± 5.68 ± 6.01 ± 1.56
MUAC cm 24.11 24.89 0.78 26.24 26.28 0.04
± 4.50 ± 4.00 ± 1.84 ± 3.05 ± 3.00 ± 1.08
BMAMA cm;': 30.03 31.54 1.51 34.72 33.77 - 0.943
10.70 8.98 5.09 + 9.34 ± 8.11 ± 3.24
S-Alb 35 - 52 g/l 30.93 3343 2.50D 32.24 31.35 - 0.88
± 8.73 ± 8.83 ± 3.92 ± 5.52 ± 5.81 ± 4.39
CRP < 10 gIl 16.66 8.62 - 8.04° 12.72 15.58 2.85
± 17.25 ± 11.12 ± 12.56 ± 26.95 ± 43.21 ± 51.95
Hb 12-18g/dl 11.27 10.71 - 0.56° 11.44 10.49 _0.95D,c
± 2.39 + 2.07 ± 0.95 + 2.35 ± 1.82 ± 1.26
MCV 80-99fl 89.51 88.67 - 0.84 86.98 87.52 0.63
6.51 5.53 4.21 7.92 6.68 5.98
MCH 27 - 31 pg 30.62 28.15 - 2.19D 30.04 28.17 _ 1.87°'c
± 3.45 ± 2.20 ± 3.04 ± 2.90 ± 2.57 ± 1.40
MCHC 33 - 37 gldl 33.22 32.06 _ 1.16°'c 34.09 32.16 _ 1.93D,c
± 0.94 ± 1.16 ± 1.15 ± 1.72 ± 2.57 ±1.44
8 Biochemical and haematological assessment for n = 17 only, one set of baseline blood
specimens lost.
b Significant change (p < 0.05) with pairwise t-test.
e Significant change (p < 0.05) with sign test.
Abbreviations: BMI = body mass index, TSF = triceps skinfold thickness, MUAC = mid-upper
arm circumference, BMAMA = Bone-free mid-upper arm muscle area, s-Alb = serum albumin,
CRP = C-reactive protein, Hb = haemoglobin, MCV = mean corpuscular volume, MCH = mean
corpuscular haemoglobin, MCHC = mean corpuscular haemoglobin concentration.
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Figure 3.1: Change in weight at follow-up visits over the study
period (n = 32)
Significant increase at 12 weeks in supplemented group (p = 0.013)
with pairwise t-test.
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Figure 3.2: Change in triceps skinfold thickness at follow-up visits over
the study period (n = 32)
Significant increase at 12 weeks in supplemented group (p = 0.047) and
placebo group (p = 0.001) with pairwise t-test.
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Figure 3.3: Mean serum albumin at baseline and at 12-week follow-up
visit (n = 31)
Significant increase in supplemented group (p = 0.033) with pairwise t-test.
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Figure 3.4: Mean C-reactive protein at baseline and at 12-week follow-up
visit (n = 31)
Significant decrease in supplemented group (p = 0.028) with pairwise t-test.
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BMI values, for example, were not distributed normally in the sample at baseline
(p = 0.008). Although distribution reached normality at follow-up visits, it may have
contributed to unequal variance between the groups. Non-parametric tests are
advisable in such cases of unevenly distributed data in small samples. The two
groups were subsequently also compared for each variable with the non-parametric
sign test. In comparing the sign test results with those of the t-test for change
between baseline and week 12, the weight increase in the supplemented group
marginally misses significance (p = 0.057) while none of the other anthropometric
results is affected. The reduced Hb in the placebo group was marginally significant
(p = 0.049) and the significance of the decrease in MCH in the placebo group and
MCHC in both groups was confirmed. The decrease in monocytes in the placebo
group was also significant (p = 0.004) with the sign test.
Although data collected at week 4 and week 8 follow-up visits were included for
analysis, no significant interim changes occurred and these data are therefore not
reported in this thesis.
3.3.1.2 Within-subject and within-group outcomes
Using the General Linear Model procedure of SAS, a number of anthropometric
parameters were shown to have responded significantly within subjects during the
study period and also in some cases significantly differently in the two groups.
Weight responded marginally significantly differently (p = 0.049) in the two groups
(Figure 3.5), while MUAC (p = 0.022) (Figure 3.6) and BMAMA (p = 0.004) (not
shown in table) showed very strong time-by-group effects within subjects. The weak
change in TSF within subjects over time (p = 0.049) was not group-dependent, and
though change in the placebo group was larger than that in the supplemented group,
this was not significant.
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Figure 3.5: Weight response over the study period (n = 32)
Significant in supplemented group (p = 0.049) with two-sided Wilcoxon
two-sample test.
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Figure 3.6: Mid-upper arm circumference response over the study
period (p =32)
Significant in supplemented group (p = 0.022) with two-sided Wilcoxon
two-sample test.
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MUAC and BMAMA increased in the supplemented group and decreased in the
placebo group and although these changes were not significant in themselves, the
differences between the two groups were significant (p = 0.022 and p = 0.004
respectively). This may be indicative of a relative maintenance of lean body tissue in
the supplemented group. WHR did not change significantly in either group and does
not indicate redistribution of body fat.
S-Alb was the only biochemical marker to respond significantly within subjects and
where the difference in change between the groups was also significant (p = 0.033)
(Figure 3.3). It would appear that the test product was able to ameliorate the extent
of hypoalbuminaemia associated with HIV/AIDS.
Among the haematological measures, Hb change was time (p = 0.001), but not
group, dependent while both MCH (p < 0.0001) and MCHC (p < 0.0001) responded
markedly differently within subjects independent of the group. The test product did
not affect the extent of the anaemia present from baseline and relatively rapid
deterioration was observed in both groups over the study period. The difference in
response of neutrophil count in the two groups was significant (p = 0.036), the
increase in the supplemented group could be indicative of the ability of the test
product to improve the neutropaenia commonly associated with HIV/AIDS, which
may reduce risk of infection. Monocytes also responded significantly (p = 0.001),
although this effect was not group dependent.
3.3.2 Immunity outcomes
With pairwise t-tests none of the immunological parameters (Table 3.3) in either
group changed significantly over the study period and none of the changes were
significantly different between the groups. Using the sign test, the decrease in
CD4+ count proved to be marginally significant in the placebo group (p = 0.049).
Although of greater magnitude, the decrease in the supplemented group remained
insignificant. CD3: COB ratio also decreased significantly (p = 0.007) in the placebo
group only. Both of the above indicate significant longitudinal immune depletion with
HIV/AIDS progression over the study period in the placebo group, but not the
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supplemented group. The test product may have contributed to the maintenance of a
relatively stable CD4+ count in the supplemented group during the study.
Table 3.3: Comparison of immunity at baseline and 12-week follow-up
visit (n = 31)
Supplemented group Placebo group
Reference n = 14 n = 17
Parameters values x±SD x±SD
and units Baseline Week 12 Change Baseline Week 12 Change
Total 0.9 - 5.2 2.66 2.11 -0.55 1.56 1.45 -0.11
lymphocytes x109/1J1 + 4.19 ± 2.15 ± 2.13 + 0.96 ± 0.90 ± 0.72
CD3+ 65 - 91% 75.43 75.57 0.14 72.42 75.35 2.94
±10.47 ± 10.28 ± 6.93 ± 13.86 ± 10.51 ± 8.07
CD4+ 500 - 1500 255.57 237.00 -28.79 212.88 198.59 -14.30a
eens/mm" ± 230.44 ± 170.68 ± 86.48 ± 184.35 ± 187.25 ± 53.91
CD8+ 230 - 800 647.46 698.62 51.15 801.29 727.18 -74.12
cetls/rnrn" ± 301.19 ± 329.26 + 175.96 ± 666.52 + 674.77 ± 561.70
CD3+: CD4+ 30 - 65 % 14.43 14.50 0.07 15.00 15.12 0.12
± 8.62 ± 8.44 ± 2.40 ± 11.17 ± 11.29 ± 5.63
CD3+: CD8+ 17 - 35 % 53.77 54.23 0.46 52.53 54.82 2.29a
± 7.25 ± 7.42 ± 6.17 ± 15.90 ± 14.83 ± 9.45
CD4+: CD8+ 1.0 - 3.5:1 0.29 0.29 -0.01 0.37 0.33 -0.04
+ 0.16 ± 0.16 ± 0,08 + 0.45 + 0.39 ± 0.18
a Statistically significant (p < 0.05) with sign test.
Immunological outcomes were also observed with individual subject assessment at
the end of the study. In only one (7%) of the supplemented subjects did the total
lymphocytes count remain below reference values, while there was an increase in
prevalence to 28% (5) in the placebo group. After the 12-week intervention
CD4+ counts < 200 cells/rnrrr' were present in 36% (5) of the supplemented group
compared to 59% (10) of the placebo group. This may represent a relatively more
stable immunity in the supplemented group than in the placebo group. Deterioration
of CD4+: CD8+ ratio (indicative of disease progression) occurred in both groups,
although not significantly in either group. All subjects, but one from the placebo
group, had values below the reference range by the end of the study for. The
findings on immunity in this study indicate that nutrition supplementation alone, in the
absence of ARV therapy, is not sufficient to curb the steady progression of HIV/AIDS.
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CHAPTER4
DISCUSSION
4.1 THESTUDYANDITSLIMITATIONS
4.1.1 Comparisonwith other studies
This pilot study is the first prospective randomised double-blind placebo-controlled
clinical trial to evaluate the effects of nutritional supplementation in people living with
HIV/AIDS in Africa and one of only a few in the world.27,80 As such, even with
a relatively small sample size, the baseline data contributes to the limited body of
data on the nutrition status of people living with HIV/AIDS in Africa.g,77 It also
provides evidence on the outcomes of nutritional supplementation with a new
micronutrient, glutamine, pre- and probiotic enriched liquid nutritional supplement on
the nutritional status and immunity in people living with HIV/AIDS.
The average study duration of nutrition intervention studies in HIV/AIDS reviewed to
date was 15 weeks.27, 80 The majority of the subjects (68%) in this study completed
the 12-week intervention period, which compares well with other studies of this
natura", even though it was neither clinic- nor outpatient-based. Similar to other
studies'", subject compliance and adherence to the study programme was
satisfactory as reported in intake diaries. No adverse effects of the intervention were
reported throughout the study period. This may be partly explained by the fact that
the subjects voluntarily subscribed to the prolonged oral nutritional supplementation
in the belief that benefit was to be derived. In addition, they were also appreciative of
the nutritional assessment and the assessment of immunity, which they would
experience for the first time and at no cost to themselves. This study confirms the
feasibility of prolonged oral nutritional supplementation in people living with
HIV/AIDS.31,35
ARV therapy was not yet freely available in South Africa at the time of the study and
none of the subjects received ARV therapy. The results of previous studies are often
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confounded by the presence of ARV therapy, which was sometimes initiated during
the research project. Subjects receiving ARV therapy at baseline and who continued
to do so throughout the study gained significantly more weight.28 The introduction of
free ARV therapy is imminent in South Africa and studies in ARV-free populations
may not be possible in the future. This implies that the independent role of nutritional
supplementation on body weight in people living with HIV/AIDS may in future not be
possible to distinguish.
4.1.2 Limitations of the study
Although the study was a prospective double-blind ramdomised controlled trial,
considered to be the gold standard for strength of evidence, certain limitations
nevertheless call for caution in the interpretation of the results. The small sample
size is a major limitation, which limits analysis of the data and may be responsible for
obscuring outcomes within subgroups and differences between the groups.
Except for the fact that all the subjects were HIV-infected, no additional clinical data
was available. The research was not performed in a clinical facility and no medical
records were available for the subjects. It is not possible to correlate the findings of
this study with the presence of fever, diarrhoea or opportunistic infection, all of which
would be expected to influence outcome. Although weight loss is often associated
with opportunistic infections and recovery from opportunistic infection is associated
with increased lean body mass", it has been reported that opportunistic infection
does not necessarily influence weight loss or the response of body weight to
nutritional counselling in HIV/AIDS.82 Without adequate clinical evaluation and
diagnosis, no conclusions can be drawn from this study with regard to the occurrence
of opportunistic infection and its association with weight loss. In the absence of ARV
therapy it is likely that opportunistic infections may have played a role in subjects who
lost weight.
Voluntary HIV-status assessment is rare in this community where patients are usually
tested only once they are ill. Precise duration of HIV infection in the sample was
therefore not known and disease stage classification was not possible at baseline.
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The data was however compared for subjects with CD4+ counts either below or
above 200 cells/mm, but no difference was apparent. Up until this study, immunity
(CD4+ counts) had never been assessed in any of the subjects.
Nutritional status data prior to the baseline evaluation was not available. No prior
weight record existed and the extent of HIV/AIDS wasting preceding this study is
unknown. It is possible that weight gain may have been more easily achieved in
subject with prior weight loss than in subjects with previously stable weight. Earlier
studies selected subjects with stable weight in order to exclude underlying weight
loss as a confounding element. 28 In this study baseline body weight was not an
exclusion criterion. Given the small sample size it was not feasible to stratify the
sample in terms of baseline weight. No difference was apparent when the data was
compared for subjects with BMI either below or above 18 kg/m2.
The study was conducted in the absence of background vitamin and/or mineral
supplementation and subjects reported excellent compliance with the study
intervention. In contrast to other studies of this nature'", baseline and background
energy and nutrient intake was not collected. Percentage weight gain is reported not
to vary by background level of energy intake28 and this is not necessarily a limitation
of this study where subgroup comparison in the small sample would not have been
feasible. On the other hand, it has been reported that nutritional supplementation
may improve background nutritional intake expressed in terms of nitrogen:energy
ratio.35
Although no socia-economic data was collected for the sample, it can be safely
assumed that the subjects, who were mostly unemployed, may have had marginal
background dietary intakes. This sets this study apart from previous studies in more
developed countries where background intake was in one instance even found to be
high in comparison with the normal population." In the latter study, it was thought
that a normal to high background energy intake is likely to render the addition of
2 100 kj (500 kcal) with a dietary supplement insufficient to result in significant
weight gain.28 The test product in this study added a mere 660 kj to the diet, which
is not considered adequate to bring about observable weight change per se over the
short duration of the present study.
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The test product was enriched with various components, and it is not possible to
distinguish the individual effects, if any, of any of these components from this study.
All findings pertain to the liquid nutritional supplement as a whole.
4.2 THE FINDINGS
4.2.1 Baseline findings
At baseline the majority of the sample was underweight when evaluated in terms of
relative body weight and BMI. As indicated by the evaluation of other anthropometric
parameters, undernutrition was not adequately identified in the subjects by weight
assessment alone. Depending on the standard used, evaluation of anthropometric
parameters produced varying prevalence values in the sample, which all point toward
a general picture of undernutrition in both groups. This relatively depleted baseline
nutritional status distinguishes this study from others in which the sample was known
to be weight-stable in the period prior to the studl8,34 and in which undernutrition
was not prevalent in the study population employed."
No statistically significant difference was found between the two groups for any of the
anthropometric parameters, but with individual nutritional assessment the
supplemented group seemed worse off when compared to individuals in the placebo
group in terms of prevalence of underweight and undernutrition based on
anthropometric parameters at baseline. When biochemical indicators were
employed, undernutrition was confirmed in half of the subjects, equally present in
both groups. Acute infection may have been present in one out of three subjects as
indicated by elevated CRP equally in both groups. Anaemia, both hypochromic,
microcytic and macrocytic, was also common at baseline.
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4.2.2 Study outcomes
The extent of body weight gain over a 12-week period in the supplemented group
was on a scale comparable to the findings of two studies of longer duration4o•35 and
exceeded the weight gain observed in other studies.23.83 This study therefore
supports the routine use of an enriched liquid nutritional supplement in order to
prevent weight loss in people living with HIV/AIDS, at least in the short to medium
term. The feasibility of nutritional supplementation as a cost-effective adjunctive
treatment for weight loss in HIV/AIDS was previously reported." The convenience of
commercial liquid nutritional supplements makes them preferable over the
cumbersome preparation of energy-dense meals."
Body weight increase in the supplemented group was associated with increases in
both lean body mass and fat mass as indicated by the significant increases in both
MUAC and TSF. This corresponds with earlier findings where fat gain
predominated.24.34 Such fat gain is associated with food intake in excess of
requirements in people living with HIV/AIDS.84 Dietary intake data was not available
in the present study and the intervention introduced too small an amount of energy to
the diet to explain the weight gain on the grounds of energy excess alone. The latter
statement implies that perhaps one or more of the supplemented ingredients of the
nutritional supplement may have played a role.
In an effort to minimise error, a single experienced observer was responsible for all
anthropometric assessments throughout the study. The significant increase in TSF in
the placebo group has no rational explanation. It is possible that the subjects,
realising they were being assessed, may have consciously or subconsciously
increased their dietary intake in an effort to obtain an outcome to satisfy themselves
and/or the researcher.
Another meaningful finding of this study is the significant increase in s-Alb in the
supplemented group associated with a significant decrease in CRP. These finding
are indicative of the amelioration of the hypoalbuminaemia often associated with
HIV/AIDS and simultaneous amelioration of inflammation in the group supplement
with the test product. These two findings together indicate that acute infections may
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have been attenuated in the supplemented group, and that the enriched supplement
may be involved in the reduction of inflammation resulting from HIVand other
infections. A similar increase in s-Alb was previously reported in malnourished
people living with HIV/AIDS who received enteral nutritional supplementatlon."
S-Alb is associated with survival" especially in women and improvement in albumin
status is particularly pertinent to this almost exclusively female sample where
increased s-Alb in the supplemented group may be a powerful independent predictor
of increased survival. 85
The test product had little effect on haematological parameters including anaemia,
which was present at baseline, and deteriorated significantly during the study period.
This would imply that the level of micronutrient supplementation in the recommended
dose of the test product is insufficient to address clinical anaemia associated with
HIV/AIDS. Although available data do not contraindicate iron supplementation in
developing countries where HIV/AIDS and iron deficiency anaemia coexlst'", iron
supplementation in HIV/AIDS may activate HIVexpression and possibly worsen
tmrnunosuppresslon." Until more is known about safe levels of iron supplementation
in HIV/AIDS, it is not advisable to increase the level of iron supplementation beyond
that which is already contained in the test product.
None of the immunity parameters was significantly affected by the intervention. In
contrast to earlier studles"' 39,40, the findings of the present study do not support the
prescription of nutritional supplementation with potentially immune-enhancing
enrichment to boost the immune system of people living with HIV/AIDS. One very
recent study" reported a significant increase in CD4+ count in subjects with
HIV/AIDS taking an immune-enhancing nutritional supplement for a period equivalent
to this study. Similar findings were however not found in either earlier or later studies
on the same product.32,40 The findings of this study thus reflect the trend found in
earlier research. It should be noted that other studies usually provided higher levels
of energy supplementation at around 2 100 to 2 520 kj (500 - 600 kcal) and it is not
known whether the extra energy alone may be responsible for at least some of the
reported findings.
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By the end of the study the nutritional status of the subjects in the present study had
changed significantly as indicated by a number of anthropometric, biochemical and
haematological evaluations (Table 4.1). Despite the mean increase in weight in the
supplemented group, the prevalence of RBW below standard increased slightly in
this group. Reassessment using BMI shows a decrease in the prevalence of
underweight in the supplemented group by the end of the study. These conflicting
results warrant scrutiny in terms of comparability of studies when different reference
standards are used.
Table 4.1: Prevalence of undernutrition in the subjects in the study at
baseline and 12-week follow-up visit (n = 32)
Indicator and standard Supplemented group Placebo group
n = 14 n = 18a
Baseline 12 weeks Baseline 12 weeks
% below % below Effect % below % below Effect
standard standard standard standard
RBW < 90% 67 71 t 58 61 t
BMI < 18 kglmL 50 36 ! 6 11 t
TSF < S" percentile 50 50 - 39 22 !
TSF < WHO standard 64 50 ! 44 17 !
MUAC < ë" percentile 57 43 ! 33 22 !
MUAC < WHO standard 51 36 ! 22 17 !
s-Alb < 35 gIl 50 43 ! 59 71 t
CRP> 10 gIl 43 33 ! 24 19 !
Lymphocytes < 0.9x10"hll 29 14 ! 29 24 !
Hb < 12 gldl 79 86 t 47 82 r
Microcytic, hypochromic 38 36 ! 24 24 -
anaemia
Macrocytic anaemia 24 36 i 20 24 t
a Biochemical and haematological parameters for n = 17 only, one set of baseline blood
specimens lost
b Significant increase (p = 0.03) with McNemar test.
Symbols: i = increased prevalence, or undesired effect
!= decreased prevalence, or desired effect
Abbreviations: RBW = relative body weight, BMI = body mass index, TSF = triceps skinfold
thickness, MUAC = mid-upper arm circumference, s-Alb = serum albumin, CRP = C-reactive
protein, Hb = haemoglobin.
The overall picture that emerged is without doubt a general state of malnutrition at
baseline, with reduction in prevalence of malnutrition over the study period as
assessed with a variety of standards. The use of different parameters and standards
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for assessment of nutritional status produced divergent results. Notwithstanding the
benefits reported in this thesis, malnutrition persisted in the sample despite nutritional
supplementation. In the absence of ARV treatment, which is the current situation in
South Africa, it seems doubtful whether nutritional supplementation will result in
marked positive changes in nutritional status.
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CHAPTERS
CONCLUSION AND RECOMMENDATIONS
5.1 CONCLUSIONS
This pilot study demonstrates that a micronutrient, glutamine, pre- and probiotic
enriched liquid nutritional supplement may promote weight gain and ameliorate
hypoalbuminaemia, inflammation and acute infection in adults living with HIV/AIDS.
The weight gain may be associated with increases in both lean body mass and fat
mass. The nutritional supplement does not appear to have an effect on the immunity
of people living with HIV/AIDS. The null hypothesis stating that the test product will
have no effect is rejected in terms of nutritional status, but upheld for immunity.
This study was limited by its small sample size. The conclusions cannot be
generalised, but can only be considered preliminary warranting further investigation.
As a pilot study the sample was not intended to be representative of the South
African HIV-infected population. The conclusions are applicable only to the sample
population, namely black adult females living with HIV/AIDS in a peri-urban
environment in a resource-poor setting. The conclusions are furthermore relevant
only to situations with limited access to medical care and to the absence of ARV
therapy.
In the absence of body weight data prior to the study, the findings cannot be
extrapolated to weight-stable subjects. Without adequate clinical data the findings of
the study cannot be associated with disease progression or extrapolated to situations
of acute opportunistic infection or clinical malabsorption. Neither of the above
limitations should be interpreted to imply that the use of nutritional supplementation is
prejudiced or precluded in these situations.
It is concluded that the use of an enriched liquid nutritional supplement is advisable in
adults living with HIV/AIDS to help prevent weight loss in the presence of
malnutrition. Although dietary counselling did not form part of this study, evidence
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from other studies indicates that nutritional supplementation is no better at fighting
weight loss associated with HIV/AIDS and is best provided in conjunction with dietary
counseling.23,25,88,89 On the basis of this study, no conclusions can be drawn that any
specific component, with which such nutritional supplements are enriched, will have
any independent effect on either nutritional status or immunity in people living with
HIV/AIDS. This study does not provide evidence for the quantity of nutritional
supplement required to achieve a beneficial effect and did not explore the
mechanisms involved.
5.2 RECOMMENDATIONS
Additional research is required on a larger sample, possibly of a multi-centre nature,
to study the effects of the enriched liquid nutritional supplement in a sample
adequately representing the diverse South African population. Further studies are
also required to evaluate the individual effects of the various components of the
enriched nutritional supplement.
Any further studies should preferably include a strong clinical component, without
which confounders such as acute infection cannot easily be eliminated. Studies
done in clinical settings will allow for more improved sampling and sample
stratification, particularly in terms of disease progression. While this study focused
on anthropometric and laboratory parameters, it will be most useful for future
research to include assessments of clinical outcomes and evaluation of quality of life.
The findings of this study contribute to the development of evidence-based nutritional
messages, which are required to counter the misinformation that has appeared in the
South African press." Nutrition policy ought to be based on scientific evidence and
should aim for the integration of messages contained in existing national guidelines
on nutrition for people living with HIV/AIDS.91 Social responsibility places the onus
on the food and pharmaceutical industries to ensure that health claims concerning
nutritional supplements are supported by evidence.
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APPENDIX 1
COMPOSITION OF THE SUPPLEMENT
Product name: B-imune®
Manufacturer: African Dynamics Pty (Ltd), Pretoria, South Africa
Ingredients: Soy protein, vegetable fat, sugar, sodium chloride,
vitamins, amino acid chelated minerals, L-glutamine,
carnitine, taurine, pre- and probiotics, flavourants and
colourant.
Nutrition lnformatlon":
Energy
Protein (fat free basis)
Fat
Carbohydrates
L-glutamine
Carnitine
Taurine
Prebiotics: Raftilose® P95 (Addendum 2)
Probiotics'": B bifidus, L acidofilis
Vitamins
Minerals
Per 100 9
1656 kJ
17.1 9
14.2 9
51.2g
5.0 9
210 mg
350 mg
7.5 9
2.0 x 109 cfu
Per 40g portion
663 kJ
6.9 9
5.7 9
20.5 9
2.0 9
84mg
140 mg
3.0 9
8.16 X 108 cfu
Per 40g portion
(For persons 10 years and older)
100% of RDA
15% of RDA
Directions for use: 1 x 40 9 sachet per day dissolved in 200ml cold water.
Flavours: Strawberry, banana and vanilla.
Store in a dry place below 25°CStorage:
a Nutrient analysis performed by the South African Bureau of Standards (SABS), Pretoria.
b Probiotic assessment performed by Agricultural Research Council (ARC), Pretoria.
cA vailable at end of 6 months period unrefrigerated.
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APPENDIX 2
MICRONUTRIENT CONTENT OF THE SUPPLEMENT
MICRONUTRIENTa Per100g Per40g %ROAb
portion per portion
VITAMINS
Biotin 250l-lg 100 I-Ig 100
Folic acid 500l-lg 250l-lg 100
Pantothenic acid 15 mg 6 mg 100
Nicotinamide 45 mg 18 mg 100
Vitamin A 2500 I-IgRE 1000 I-IgRE 100
Vitamin B1 3.5 mg 1.4 mg 100
Vitamin B2 4.0mg 1.6 mg 100
Vitamin B6 5.0 mg 2.0 mg 100
Vitamin B12 2.51-1g 1.0 I-Ig 100
Vitamin C 150 mg 60 mg 100
Vitamin 03 12.5 I-Ig 5.01-lg 100
Vitamin E 37.5 mg a-TE 15.0 mg a-TE 100
MINERALS
Calcium 300 mg 120 mg 15
Iron 5.3 mg 2.1 mg 15
Zinc 5.6mg 2.3mg 15
Selenium 20.61-1g 8.31-1g 15
Chromium 37.51-1g 151-1g c
Manganese 0.8 mg 0.3 mg c
a Nutrient analysis performed by the South African Bureau of Standards (SABS), Pretoria.
b RDA for persons 1Dy and older.
C No RDA available.
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APPENDIX 3
COMPOSITION OF THE PREBIOTIC COMPONENT
OF THE SUPPLEMENT
Product name: Raftilose® P95
Supplier: Orafti, Tienen, Belgium
Description: A powder containing mainly oligofructose produced by partial
enzymatic hydrolysis of chicory inulin and a food ingredient
composed of oligofructose (> 93.2%) and fructose, glucose and
sucrose « 6,8% together).
Safety: Safe. Non-toxic. Not dangerous. Excessive consumption may
cause diarrhoea.
Nutritional informatlon":
Average per 100g
Carbohydrates
Sugars
Dietary fibre
Protein
Fat
Vitamins and minerals
Energy
5
5
92
o
o
Negligible
158kcal/662 kj
a Information provided by supplier.
Stellenbosch University http://scholar.sun.ac.za
64
APPENDIX 4
RESEARCH PROTOCOL
TITLE
THE EFFECTS OF A MICRONUTRIENT, GLUTAMINE, PRE- AND PROBIOTIC
ENRICHED FOOD SUPPLEMENT ON THE NUTRITIONAL STATUS AND
IMMUNITY OF ADULTS LIVING WITH HIV/AIDS: A PILOT STUDY
RESEARCHERS
Chief researcher
Roy D Kennedy B Nutr (Stell), RD(SA)
Department of Human Nutrition, Medunsa
Co-researchers
Willa Haasbroek M Sc
Consultant Food Scientist, Gauteng
INTRODUCTION
It is estimated that 70% of the HIV positive population of the world reside in Sub-
Saharan Africa (ACC/SCN 2001). In South Africa alone 40% of deaths have been
ascribed to AIDS-related disease (MRC 2002). The impact of HIV/AIDS is felt at all
levels of society, in the health system, the workforce, the economy and human
development (ING Barings 2000, UNAIDS 1998).
The metabolic effects of HIV on the infected individual are numerous and well
described (Kotler 1999). Influenced by reduced food intake, nutritional alterations
and complications of HIV/AIDS, the nutritional status is greatly compromised (Piwoz
and Preble 2000). Furthermore, social isolation, physical disability and
unemployment impact on the progression of HIV/AIDS. HIV/AIDS and the
accompanying malnutrition both suppress the immune system of the person living
with the virus. Although some evidence exists for the benefits of immunonutrient
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supplementation (eg glutamine, arginine and antioxidant nutrients) in physically
stressed patients receiving enteral and/or parenteral nutrition support, no clear
recommendations exist (Barton 1997) and very few studies have been published with
regard to HIV infection (Kotler 2000).
Although it is well documented that the maintenance of body weight, and in particular
lean body tissue, impacts positively on survival in HIV/AIDS (Kotler et al. 1989, Kotler
1999), documented evidence of the benefit of food-based nutrition intervention in
HIV/AIDS is sadly lacking (Kotler 2000). Even though a small number of studies
have indicated improved clinical outcomes, there is similarly a paucity of data on the
effectiveness of supplemental nutrition support in HIV/AIDS (Stack et al. 1996, Kotler
2000). There exists a great need for the examination of the effects of supplemental
oral feeds in terms of outcomes such as weight and immunity.
The availability of a new enriched food supplement on the market, offers the
possibility of affordable nutrition intervention to people living with HIV/AIDS with the
added benefit of added micronutrients and immunonutrients, which may support the
immune system. In the light of the economic effects of HIV/AIDS and household food
security, it is vitally important to ascertain the effectiveness of such a product on the
nutritional status and immunity before any unsubstantiated health claims are made. A
prospective, longitudinal study on the effectiveness of supplemental feeding in
HIV/AIDS will contribute not only to the care of people living with HIV/AIDS in South
Africa, but also internationally
AIM
The primary aim of the study is to determine the effects of a micronutrient, glutamine
and pre- and pro-biotic enriched food supplement on the nutritional status and
immunity of adults living with HIV/AIDS.
OBJECTIVES
The study intends to determine the effects of the enriched food supplement on:
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1 the nutritional status of people living with HIV/AIDS by means of
anthropometric and biochemical assessment over a period of 90 days.
2 the immune system of people living with HIV/AIDS by means of CD3+, CD4+
and CD8+ counts and their respective ratios over a period of 90 days.
HYPOTHESIS
It is hypothesised that the test feed will have no effect on either the nutritional status
or the immunity of the subjects.
TYPE OF STUDY
A randomised double-blind placebo controlled study is planned where the test group
will receive the enriched food supplement (the test feed) and the control group a
specially formulated placebo drink without enrichment (the placebo feed).
THE SAMPLE
The convenience sample will comprise free-living adults attending the Moreteie
Sunrise Hospice, a community-based centre in Temba, Hammanskraal, North-West
Province, located 50 km north of Pretoria. This sample will be randomly divided into
a test group (those who receive the test feed) and a control group (those who receive
the placebo) in a double-blind manner.
It is aimed to include at least 40 male and female subjects with HIV/AIDS
independent of duration of infection. All stages of HIV infection will be included
whether asymptomatic or symptomatic. Confidentiality will be ensured at all times
and the subjects will be identifiable by a number consecutively allocated upon entry
into study alone.
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EXCLUSION CRITERIA
• The study will focus on adults only and anyone younger than 21 years will be
excluded.
• The study will focus on HIV positive individuals and uninfected persons will be
excluded.
• The study will focus on the effects of the enriched food supplement and persons
on antiretroviral drug treatment will be excluded.
• The study aims to determine the effects of the enriched food supplement and
any person who initiates the taking of other nutritional or immune-enhancing
supplements during the study will be excluded.
• The study will require assurance of the regular intake of the supplemental feed.
For this purpose persons in the terminal stage of the disease, who may find this
problematic, will be excluded from the study. Because terminal patients are not
likely to visit the clinic, it precludes the possible ethical dilemma of their
exclusion from the study.
• Pregnant females will be excluded from the study.
METHOD
The manufacturers of the food supplement, B-imune® [for composition see
Appendices 1 and 2], will supply sufficient quantities of the test and placebo feed to
augment the existing diet of the subjects with one feeds per day for 84 days each.
The convenience sample will be randomly divided, with one half of the subjects to
receive the test feed (the complete product with micronutrient, glutamine and pre-
and pro-biotic enrichment) and the other half the placebo feed. The placebo feed is
formulated to be comparable in flavour and colour to the test feed. A low-energy
bulking agent is used to arrive at a similar dry weight to that of the test feed, but with
minimal energy content [Appendix 4].
The manufacturer will supply the feeds in numbered packaging (84 feeds for each
number). The feeds will be pre-coded, identifying test and placebo feeds in a code
not known to either the researchers or subjects. Decoding will only be done on
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completion of the study and once all data had been collected. Each subject will
receive a plastic mixer with marked volume measurements to ensure standard
preparation of the supplement.
Before intervention, baseline data will include anthropometric, biochemical and
haematological assessment of nutritional status and baseline assessment of
immunological status. Upon each visit a basic health history will be taken to record
health and nutritional problems.
The intervention will comprise once-daily recorded ingestion of either the test or
placebo feed. The identity of the type of feed will be unknown to both the
researchers and the subjects. The subjects will additionally continue with their home
diets as usual. Any current or newly initiated use of nutritional of immune-enhancing
supplements is to be reported.
The subjects will be provided with contact details to report any unforeseen
circumstances. Subjects will be required to keep a daily record of consumption of the
food supplement, problems and symptom. Any illness or infection must be recorded,
as well as any factors influencing compliance with the ingestion of the supplement.
A registered dietitian will assess the following anthropometric parameters at baseline
and thereafter every 28 days to the completion of the study period:
Height
Weight
Body mass index (calculated from the above)
Triceps skinfold
Arm muscle circumference
Waist circumference
Hip circumference
WaisUhip ratio
The following biochemical and haematological parameters will be assessed at
baseline and on completion of the study after 84 days and all blood samples will be
collected by a registered nursing practitioner:
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Serum total protein
Serum albumin
C-Reactive protein
Full blood count
CD3+, CD4+ and CD8+ counts (with ratios)
STATISTICS
The University of Stellenbosch will appoint a statistician, in conjunction with whom
the researcher will analyse the data. Anthropometric and biochemical data will be
compared with standards and normal values. Immunological assessment will be
compared with diagnostic criteria used in HIV/AIDS classification. The results of the
two groups will be compared using information technology based statistical
programmes to determine significance of difference between the test and control
groups.
LIMITATIONS
• The small study sample may limit generalisation of the results to a larger
population.
• The stage of HIV infection may influence outcome in individual subjects.
• Regular visits may influence results independently from the food supplement
that is being tested.
BUDGET
The manufacturers of the test feed will be responsible for the costs pertaining to the
research project in full. The major costs involved relate to the biochemical and
haematological assessments, which will be performed by the laboratories at
Medunsa and for which the quotes run to around R 45 000 in total. The only
additional costs will include traveling cost to and from the research site. No staff
remuneration is planned for and equipment from the Department of Human Nutrition
at Medunsa will be used free of charge.
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ETHICS
• Approval for the study will be sought from the Research and Ethics Committee
of the Faculty of Health Sciences of the University of Stellenbosch.
• Written informed consent [Information and informed consent document:
Appendix SJ will be obtained from the subjects prior to commencement of the
study.
• Confidentiality of information will be observed at all times and a unique coding
system will be used to refer to subjects.
TIME FRAME
It is planned to initiate the intake of subjects into the study during January 2003 for
the study to be completed by the end of April 2003. The final research report
deadline is set for 30 June 2003.
REPORT
The study forms part of the requirements for the Masters in Nutrition degree at the
University of Stellenbosch and will be reported in a dissertation. It is also planned to
submit a paper on the study to a professional journal in the fields of nutrition and
dietetics, hopefully internationally.
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APPENDIX 5
COMPOSITION OF THE PLACEBO
Strawberry flavour g/200ml %
Total 40.000 100.000
Unidry 20 (Maltodextrin) 38.386 95.965
Cloud MB92538 0.200 0.500
Ti02 (Titanium dioxide) 0.200 0.500
Salt 0.200 0.500
Sweetener blend 80x (doI06) 0.150 0.375
CMC 3000 (Carboxymethyl Cellulose) 0.500 1.250
Flavourant: Vanilla 564340SPM 0.200 0.500
Flavourant: Strawberry 564.477 SPM 0.1600 0.400
Colourant: Carmoisine Red H711 0 0.0040 0.010
Banana flavour g/200ml %
Total 40.000 100.000
Unidry 20 (Maltodextrin) 38.546 96.365
Cloud MB92538 0.200 0.500
Ti02 (Titanium dioxide) 0.200 0.500
Salt 0.200 0.500
Sweetener blend 80x (doI06) 0.150 0.375
CMC 3000 (Carboxymethyl Cellulose) 0.500 1.250
Colourant: Tartrazine H7061 0.004 0.010
Flavourant: Vanilla 564340SPM 0.200 0.500
Flavourant: Banana 564.006 SPM 0.130 0.325
Vanilla flavour g/200ml %
Total 40.0000 100.000
Unidry 20 (Maltodextrin) 38.550 96.375
Cloud MB92538 0.200 0.500
Ti02 (Titanium dioxide) 0.200 0.500
Salt 0.200 0.500
Sweetener blend 80x (doI06) 0.150 0.375
CMC 3000 (Carboxymethyl Cellulose) 0.500 1.250
Flavourant: Vanilla 564340SPM 0.200 0.500
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APPENDIX 6
STUDY INFORMATION AND INFORMED CONSENT DOCUMENT
TITLE OF THE RESEARCH PROJECT:
THE EFFECTS OF A MICRONUTRIENT, GLUTAMINE, PRE- AND PROBIOTIC
ENRICHED FOOD SUPPLEMENT ON THE NUTRITIONAL STATUS AND
IMMUNITY OF ADULTS LIVING WITH HIV/AIDS: A PILOT STUDY
REFERENCE NUMBER: 2002/C/102
PRINCIPAL INVESTIGATOR: Mr R 0 Kennedy
ADDRESS: Department of Human nutrition
POBOX 177
MEDUNSA 0204
DECLARATION BY PARTICIPANT
I, THE UNDERSIGNED, (name),
ID No: , hereafter called the participant, of
••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• '0' ••••• (address).
A. HEREBY CONFIRM AS FOllOWS:
1. I was invited to participate in the abovementioned research project, which is
being undertaken by the Department of Human Nutrition, Faculty of Health
Sciences, University of Stellenbosch.
2 The following aspects have been explained to me:
2.1 Aim: The aim of the project is to determine the effects of a food supplement
on the nutrition and immunity of adults living with HIV/AIDS.
Continued overleaf/ ...
Stellenbosch University http://scholar.sun.ac.za
74
2.2 Procedures: The nature of the project requires me to take either the food
supplement or a product that looks and tastes similar. Neither I, nor the
investigator, will know which product I will be taking.
• The project will last for 84 days.
• It is important that I should report the taking of any nutritional
supplements (vitamins or minerals, eg calcium or iron) at the beginning of
the study and that I should inform the investigator when starting to take
any supplements.
• I will need to visit the clinic on the first day of the project and thereafter
every 28 days until the completion of the project after 84 days (a total of 4
visits).
• During the first and last visits, a 10 ml sample of blood (about 2
teaspoons) will be required to measure levels of immunity and nutrition.
2.3 Risks: There are no known risks or side effects of the food supplement
when taken at the amount prescribed (40g or 200 ml per day) for the study.
Excessive intake may lead to diarrhoea.
2.4 Possible benefits: The food supplement is designed to boost the immune
system and improve the level of nutrition. The results of this project will
benefit other people living with HIV/AIDS.
2.5 Confidentiality: The information collected, as well as my medical and
personal information will be treated as confidential. I agree that the
information may be used for publication in professional journals and that it
may be included in a thesis provided my identity is kept confidential.
2.6 Access to findings: Upon request, the investigator will inform me of my
results obtained in the project, but it will not be revealed to other persons.
2.7 Voluntary participation/refusal/discontinuation: Participation in the
project is voluntary and I may refuse to participate in the project. The
investigator may withdraw me from the project should he/she feel that it
would be in my best interest or if I have not follow the agreements hereby
agreed to. I understand that I will be excluded from the project if I should
start to take anti-retroviral medication during this period.
3 The information above was explained to me by:
............................................................. (name of relevant person) in
English and I am in command of this language/was satisfactorily translated
to me by:
............................................................................ (name of translator).
Continued overleaf/ ...
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4 I was given the opportunity to ask questions and all these questions were
answered satisfactorily.
B I HEREBY CONSENT VOLUNTARILY TO PARTICIPATE IN THE ABOVE-
MENTIONED PROJECT.
Signed/confirmed at on 2003
(place) (date)
Signature of participant Signature of witness
STATEMENT BY OR ON BEHALF OF INVESTIGATOR
I, (name of investigatorlrepresentative)
declare that I explained the information given in this document to:
................................................................................... (name of participant);
he/she was encouraged and given ample time to ask me any questions;
this conversation was conducted in English and no translator was used/
this conversation was translated into (language)
by , (name of translator).
Signed/confirmed at on 2003
(place) (date)
Signature of investigatorlrepresentative Signature of witness
Continued overleaf/ ...
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DECLARATION BY TRANSLATOR
I, (name), confirm that I:
• translated the contents of this document from English into
...................................... (language) to the participant;
• explained the contents of this document to the participant;
• also translated the questions posed by the participant, as well as the
answers given by the investigator;
• and conveyed a factually correct version of what was related to me.
Signed/confirmed at on 2003
(place) (date)
Signature of translator Signature of witness
IMPORTANT MESSAGE TO PARTICIPANT
Dear participant,
Thank you for your participation in this study.
Should, at any time during the study:
• an emergency arise as a result of the research, or
• you require any further information with regard to the project, or
• you start to take other nutritional supplements,
kindly contact Mr R Kennedy on 082-575-6507 or 012-521-4078
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APPENDIX 7
EXAMPLE OF SUBJECT IDENTIFICATION CARD
FRONT
STUDY NUMBER
25
REVERSE
YOUR NEXT APPOINTMENT:
1 __ '__ '2003
2 __ '__ '2003
3 __ '__ '2003
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APPENDIX 8
SUBJECT INFORMATION RECORD
SUBJECT INFORMATION SHEET
Initials: _
Date of birth:
CONFIDENTIAL
SUBJECT NO: AD _
SEX: M / F
Surname: _
__ /__ /19
Physical address: _
Race:
Home language:
Duration if infection:
Disclosed:
________ Code__
(0_)_- _
(0_)_- _
(0_)_- _
(0_)_- _
Home telephone:
Work telephone:
Fax:
Cell phone:
Black / White / Coloured / Indian
State number of years _
No / Yes
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APPENDIX 9
SUPPLEM ENT DISTRIBUTION RECORD
CLINICAL TRIAL
PRODUCT DISTIBUTION SHEET
MONTH 3
DATE SUBJECT NO SIGNATURE
1
2
3
4
5
46
47
48
49
50
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APPENDIX 10
DAILY SUPPLEMENTAL INTAKE RECORD
CLINICAL TRIAL
INTAKE RECORD 3 (Final)
SUBJECT NO: AD
Feed Month Date Tick List any health and feeding problems in this column
No when especially if it affects your ability to take the product
taken
1 March 25
2 March 26
3 March 27
4 March 28
5 March 29
6 March 30
7 March 31
8 April 1
9 April 2
10 April 3
11 April 4
12 April 5
13 April 6
14 April 7
15 April 8
16 April 9
17 April 10
18 April 11
19 April 12
20 April 13
21 April 14
22 April 15
23 April 16
24 April 17
25 April 18
26 April 19
27 April 20
28 April 21
YOUR NEXT AND LAST VISIT IS ON 22 APRIL 2003
I, the participant identifiable by the number above, hereby state that the record
above is a true reflection of my participation in the clinical trial.
Signed:
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APPENDIX 11
SPECIMEN COLLECTION PROTOCOL
CLINICAL TRIAL
BLOOD COLLECTION PROTOCOL
IMPORTANT NOTICE:
1 Clearly mark each tube with the subject number
2 All samples must be ready for transport to MEDUNSA laboratories at 13HOO
INSTRUCTIONS:
A Blood sample required for Haematology:
Collect at least 4ml of venous blood in an EDTA tube (purple top)
Mix gently by tilting the tube 6-8 times
Place sample in cooler box
B Blood sample required for Chemical Pathology:
Fill a red-topped tube (5ml) with venous blood
Place sample in cooler box
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